Towards strengthening the emerging biotechnology enterprise in India, Department of Biotechnology (DBT) Ministry of Science & Technology has initiated the Mission Program entitled “Industry-Academia Collaborative Mission for Accelerating Discovery Research to Early Development for Biopharmaceuticals – Innovate in India (I-3) Empowering biotech entrepreneurs & accelerating inclusive innovation” (“Program”).
The program was approved by the Cabinet for implementation in May 2017 and formally launched by Hon’ble Minister for Science & Technology on 30th June, 2017 with a total cost US$ 250 million (of which 50% will be arranged through World Bank). Biotechnology Industry Research Assistance Council (BIRAC) setup by DBT is the Implementing Agency of the programme.
The Legal Agreement with World Bank for flexible financing arrangements for this Mission of DBT was executed on April 24, 2018 between the project implementing agency – BIRAC a PSU of DBT, Department of Economic Affairs, Ministry Finance, Govt. of India and International Bank for Reconstruction and Development (on behalf of World Bank). This mission will mark the beginning of a new partnership between DBT and World Bank; it is envisaged that this programme will revolutionize the Biotech market. It will help deliver 6-10 new products in the next five years, create several dedicated facilities for next-generation skills, and hundreds of jobs in the process. It is anticipated that in the long term it would benefit the Indian population at large due to availability of affordable solutions and products relevant to Indian health needs.
The main aim of this Pan-India Programme is to make India a hub for design and development of novel, affordable and effective biopharmaceutical products and solutions. This Program would aid in enhancing India’s innovation research and product development capabilities, especially by focusing on development of vaccines, biologics and medical devices for combating public health concerns. The Program would aid academic researchers (through enhancing their translation capability); empower bio-entrepreneurs and SMEs (by decreased cost and risk during early stages of product development) and the industry (by elevating their innovation quotient).
The programme will also bring isolated centers of excellence together, enhance regional capabilities and strengthen the current bio-clusters network in terms of capacities as well as quantity and quality of output. The Mission will strengthen and create shared infrastructure for product development and Centre of Excellences for knowledge generation and skill development for Technology Strengths and Technology Management. This mission will develop platform technologies for product validation, link institutions to strengthen clinical trial networks and build capacities in emerging areas.
This will be a great platform which will offer buoyancy as well as universal support to biotechnological innovation, and transform India into a global hub for cutting-edge biotechnology research and development. The programme will help deliver 6-10 new products in the next five years, create several dedicated facilities for next-generation skills, and hundreds of jobs in the process. Anticipated long-term impact would benefit the Indian population at large due to availability of affordable solutions and products relevant to Indian health needs.